ACNÉ SEVERO PUBLICACIONES CIENTÍFICAS

28

Jul 2017

ISOTRETINOIN TREATMENT FOR ACNE AND RISK OF DEPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Huang YC1, Cheng YC2.

ABSTRACT

BACKGROUND:

The relationship between isotretinoin treatment for acne and depression is controversial. Quantitative analysis has not yet been conducted.

OBJECTIVES:

To conduct a meta-analysis, evidence-based examination of the relationship between isotretinoin and depression.

METHODS:

A systematic review and meta-analysis of the literature published from inception to September 30, 2016, was conducted. Controlled or prospective non-controlled trials on ≥15 acne patients receiving isotretinoin treatment were included. The prevalence of depression and change in depression scores were calculated.

RESULT:

Thirty-one studies met the inclusion criteria. In the controlled studies, the change in depression scores from baseline was not significantly different between patients receiving isotretinoin treatment and those receiving an alternative treatment (standardized mean difference [SMD] -0.334, 95% confidence interval [CI] -0.680 to 0.011). The prevalence of depression after isotretinoin treatment significantly declined (relative risk [RR] 0.588, 95% CI 0.382-0.904). The mean depression scores significantly decreased from baseline (SMD -0.335, 95% CI -0.498 to -0.172).

LIMITATIONS:

No randomized controlled trials were reviewed; a large inter-study variation was observed.

CONCLUSIONS:

Isotretinoin treatment for acne does not appear to be associated with an increased risk for depression. Moreover, the treatment of acne appears to ameliorate depressive symptoms.

doctor

COMENTARIOS

Dra. Ariadna Ortiz Brugués, Ph. D., dermatóloga y directora médica Pierre Fabre Dermocosmética

En el presente artículo los autores realizan un meta-análisis sobre la posible relación entre el tratamiento con isotretinoína y el riesgo de depresión. Analizan un total de 30 estudios que cumplen los criterios de inclusión, y observan que no existe diferencia en el riesgo de depresión entre los pacientes que reciben el tratamiento frente a los que reciben un tratamiento alternativo. Más aún, la prevalencia de depresión es significativamente menor tras el tratamiento con isotretinoína frente al grupo control. Por tanto, los autores concluyen que no solamente la toma de isotretinoína no parece estar relacionada con un mayor riesgo de depresión, sino que este tratamiento parece mejorar los síntomas depresivos.

“Observan que no existe diferencia en el riesgo de depresión entre los pacientes que reciben el tratamiento frente a los que reciben un tratamiento alternativo.”

Juntos Contra el acné

Una iniciativa de Pierre Fabre Dermatologie una marca de Pierre Fabre Ibérica.